Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Studie fáze 1 se zvyšováním dávky SLV 154 u subjektů s metastatickými solidními nádory

18. září 2026 aktualizováno: Solve Therapeutics

This is a Phase 1 study comprising a Phase 1a dose-escalation portion and a Phase 1b expansion portion evaluating the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of SLV-154 across a range of dose levels when administered to subjects with advanced solid tumors.

Přehled studie

Detailní popis

A Bayesian optimal interval (BOIN) design with a target dose-limiting toxicity (DLT) rate for the maximum tolerated dose (MTD) of 27% and an estimated maximum sample size of ~70 subjects will be used to guide the dose escalation and determine the recommended dosing regimen (RDR) of SLV-154. Once the initial RDR is established in the Phase 1a portion of this study, further development in the Phase 1b expansion portion of this study will be considered in patients with specific cancers. In the Phase 1b part of this study, enrollment of each tumor-specific cohort will be performed using a Simon 2-stage optimal design.

SLV-154 will be administered intravenously (IV) in repeated 3-week cycles. Treatment will continue until progressive disease or discontinuation.

Typ studie

Intervenční

Zápis (Odhadovaný)

250

Fáze

  • Fáze 1

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

Studijní záloha kontaktů

  • Jméno: Hong Ren, MD
  • Telefonní číslo: 425-894-2558
  • E-mail: hren@solvetx.com

Studijní místa

    • California
      • Newport Beach, California, Spojené státy, 92663
        • Nábor
        • Hoag Memorial Hospital Presbyterian
        • Kontakt:
    • Missouri
      • St Louis, Missouri, Spojené státy, 63110
        • Nábor
        • Washington University
        • Kontakt:
    • New Jersey
      • East Brunswick, New Jersey, Spojené státy, 08816
    • New York
      • New York, New York, Spojené státy, 10065
        • Nábor
        • Memorial Sloan Kettering Cancer Center
        • Kontakt:
    • Ohio
      • Cleveland, Ohio, Spojené státy, 44106
        • Nábor
        • University Hospitals Cleveland Medical Center
        • Kontakt:
      • Columbus, Ohio, Spojené státy, 43210
        • Nábor
        • The James Outpatient Care West Center
        • Kontakt:
    • Pennsylvania
      • Philadelphia, Pennsylvania, Spojené státy, 19111
    • Texas
      • Houston, Texas, Spojené státy, 77030
        • Nábor
        • MD Anderson Cancer Center
        • Kontakt:
      • Houston, Texas, Spojené státy, 77030
      • San Antonio, Texas, Spojené státy, 78229
        • Nábor
        • Mays Cancer Center; University of Texas Health San Antonio
        • Vrchní vyšetřovatel:
          • Daruka Mahadevan
        • Kontakt:
    • Washington
      • Seattle, Washington, Spojené státy, 98109
        • Nábor
        • University of Washington / Fred Hutchinson Cancer Center
        • Kontakt:
      • Tacoma, Washington, Spojené státy, 98405
        • Nábor
        • Northwest Medical Specialties, PLLC
        • Kontakt:
        • Kontakt:

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

12 let a starší (Dítě, Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

  1. Men or women (as appropriate for cancer type) of age ≥12 years.
  2. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  3. Histologically or cytologically confirmed diagnosis of advanced cancer as documented in medical records.
  4. Presence of metastatic or recurrent locally advanced cancer.
  5. Presence of radiographically measurable disease.
  6. Prior receipt of one or more commercially available therapies that are indicated within product labelling or recommended under current guidelines as appropriate treatment for the subject's cancer (unless evolving data support application of SLV-154 in previously untreated subjects with high unmet medical need and inadequate and/or poorly tolerated treatment options).
  7. Availability of tumor tissue from a fresh tumor biopsy obtained by a core needle, excisional, or incisional biopsy; or punch biopsy (for cutaneous disease); or archival tumor sample from a previous biopsy.
  8. Availability of computed tomography (CT) or magnetic resonance imaging (MRI) of chest, abdomen, and pelvis, and/or fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT (if appropriate for tumor type) (with PET from base of the skull to mid-thigh, if performed) within 35 days before study drug administration.
  9. Completion of all previous therapy (including surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, or investigational therapy) for the treatment of cancer ≥1 week before the start of study drug administration.
  10. Adequate hematological profile.
  11. Adequate coagulation profile.
  12. Adequate hepatic profile.
  13. Adequate renal function.
  14. Negative viral serology or adequate therapy for human immunodeficiency virus (HIV), hepatitis B (HBV), and hepatitis C (HCV) infection.
  15. For female subjects of childbearing potential, a negative serum pregnancy test.
  16. For female subjects of childbearing potential, willingness to use a protocol-recommended method of contraception from the start of the screening period until ≥6 months after the final dose of study therapy.
  17. For male subjects who can father a child and are having intercourse with females of childbearing potential who are not using adequate contraception, willingness to use a protocol-recommended method of contraception from the start of study therapy until ≥6 months after the final dose of study therapy and to refrain from sperm donation from the start of study therapy until ≥12 months after administration of the final dose of study therapy.
  18. Willingness and ability of the subject to comply with scheduled visits, the drug administration plan, protocol-specified laboratory tests, other study procedures (including required tumor biopsy/aspirations and/or radiographic studies), and study restrictions.
  19. Evidence of a personally signed informed consent indicating that the subject is aware of the neoplastic nature of the disease and has been informed of the procedures to be followed, the experimental nature of the therapy, alternatives, potential risks and discomforts, potential benefits, and other pertinent aspects of study participation.

Exclusion Criteria:

  1. Unstable malignancy involving the central nervous system.
  2. Presence of another cancer with disease manifestations or therapy that could adversely affect subject safety or longevity, create the potential for drug-drug interactions, or compromise the interpretation of study results.
  3. Uncontrolled ongoing systemic bacterial, fungal, or viral infection (including upper respiratory tract infection) at the time of start of study therapy.
  4. Significant cardiovascular event or comorbidity.
  5. Significant screening ECG abnormalities.
  6. Pregnancy or breastfeeding.
  7. Major surgery within 3 weeks before the start of study therapy.
  8. Use of a strong inhibitor or inducer of CYP3A4 or CYP1A2.
  9. Concurrent participation in another therapeutic or imaging clinical trial.
  10. Other conditions likely to interfere with a subject's ability to participate in the study.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Nerandomizované
  • Intervenční model: Sekvenční přiřazení
  • Maskování: Žádné (otevřený štítek)

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: Dose Level 1

0.75 mg/kg

SLV-154

Experimentální: Dose Level 2

1.5 mg/kg

SLV-154

Experimentální: Dose Level 3

3.0 mg/kg

SLV-154

Experimentální: Dose Level 4

4.0 mg/kg

SLV-154

Experimentální: Dose Level 5

5.0 mg/kg

SLV-154

Experimentální: Dose Level 6

6.5 mg/kg

SLV-154

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Phase 1a: MTD and/or RDR
Časové okno: Through the duration of treatment, up to approximately 18 months

Determination of the MTD (maximum tolerated dose) and/or RDR (recommended dosing regimen) for SLV-154.

Through the duration of treatment, up to approximately 18 months
Phase 1b: Objective response rate (ORR)
Časové okno: Through the duration of treatment, up to approximately 18 months

ORR assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 criteria and defined as the percentage of participants with confirmed complete response (CR) or confirmed partial response (PR).

Through the duration of treatment, up to approximately 18 months

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
SLV-154 administration
Časové okno: Through the duration of treatment, up to approximately 18 months

SLV-154 drug administration as assessed by prescribing records

Through the duration of treatment, up to approximately 18 months
SLV-154 Safety
Časové okno: Through the duration of treatment, up to approximately 18 months

Collection of type, frequency, severity, timing of onset, duration, and relationship to study drug of any treatment-emergent adverse events (TEAEs); laboratory abnormalities; vital sign/oxygen saturation abnormalities; adverse electrocardiogram (ECG) findings; DLTs; serious adverse events (SAEs); adverse events of special interest (AESIs); or adverse events (AEs) leading to interruption, modification, or discontinuation of study drug administration.

Through the duration of treatment, up to approximately 18 months
Evaluation of use of concomitant medications
Časové okno: Through the duration of treatment, up to approximately 18 months

Type, frequency, and timing of use of supportive care and other concomitant medications

Through the duration of treatment, up to approximately 18 months
SLV-154 Pharmacokinetics
Časové okno: Varying timepoints through the duration of treatment, up to approximately 18 months

Evaluation of the pharmacokinetic profile of SLV-154

Varying timepoints through the duration of treatment, up to approximately 18 months
Immunogenicity
Časové okno: Varying timepoints through the duration of treatment, up to approximately 18 months

Measurement of changes in titers of circulating SLV 154-reactive antibodies (as assessed using immunoassay methods)

Varying timepoints through the duration of treatment, up to approximately 18 months
Time to Response (TTR)
Časové okno: Up to approximately 36 months

TTR: interval from the start of study drug administration to the first documentation of objective tumor regression

Up to approximately 36 months
Duration of Response (DOR)
Časové okno: Up to approximately 36 months

DOR: interval from the first documentation of objective tumor regression to the earlier of the first documentation of disease progression or death from any cause

Up to approximately 36 months
4-month progression-free survival (PFS4)
Časové okno: Up to approximately 36 months

PFS4: proportion of subjects who are alive and have not experienced disease progression at 4 months after the start of study drug administration

Up to approximately 36 months
6-month progression-free survival (PFS6)
Časové okno: Up to approximately 36 months

PFS6: proportion of subjects who are alive and have not experienced disease progression at 6 months after the start of study drug administration

Up to approximately 36 months
Time to treatment failure (TTF)
Časové okno: Up to approximately 36 months

TTF: interval from the start of study drug administration to the earliest of the first documentation of disease progression, the permanent cessation of study drug due to an AE, or death from any cause

Up to approximately 36 months
Overall survival (OS)
Časové okno: Up to approximately 36 months

OS: interval from the start of study drug administration to death from any cause

Up to approximately 36 months
Disease benefit ratio (DBR)
Časové okno: Up to approximately 36 months

DBR: proportion of subjects who experience CR, PR, or stable disease with tumor reduction (SDTR)

Up to approximately 36 months
Progression free survival (PFS)
Časové okno: Up to approximately 36 months

PFS: interval from the start of study drug administration to the earlier of the first documentation of disease progression or death from any cause

Up to approximately 36 months
Duration of disease benefit (DDB)
Časové okno: Up to approximately 36 months

DDB: interval from the first documentation of objective tumor regression to the earlier of the first documentation of disease progression or death from any cause in subjects with disease benefit

Up to approximately 36 months
Percent change in tumor dimensions
Časové okno: Up to approximately 36 months

percent change from baseline in the sum of the longest diameters of non-nodal target lesions and the shortest diameters of nodal target lesions

Up to approximately 36 months

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

14. května 2025

Primární dokončení (Odhadovaný)

1. srpna 2027

Dokončení studie (Odhadovaný)

1. listopadu 2027

Termíny zápisu do studia

První předloženo

3. ledna 2025

První předloženo, které splnilo kritéria kontroly kvality

9. ledna 2025

První zveřejněno (Aktuální)

13. ledna 2025

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

22. září 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

18. září 2026

Naposledy ověřeno

1. září 2026

Více informací

Termíny související s touto studií

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

NE

Popis plánu IPD

Results will be presented in clinical study reports and publications. Individual participant data will not be shared with other researchers.

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ano

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Předplatit